Perrigo Company has received tentative approval from the US Food and Drug Administration for the generic version of Braintree Laboratories' Suprep (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution. The drug is indicated for the treatment of cleansing of the colon in preparation for colonoscopy in adults. Braintree Laboratories is a pharmaceutical company based in Braintree, Massachusetts. Annual sales for Suprep in the past 12 months ending July 2016 were $178 million.

In other news, Perrigo has also been sued by Galderma Laboratories and Nestle Skin Health over Perrigo's abbreviated new drug application filing for the generic version of Galderma's Mirvaso (brimonidine) topical gel .33%, which is indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. Annual sales for Mirvaso for the past 12 months ending July 2016 were $34 million. Galderma is a joint venture owned by Nestlé and L'Oréal.

Source: Perrigo